Home › Compare › VBLT vs EQR

VBLT vs EQR: Dividend Comparison 2026

VBLT yields 1282.05% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VBLT wins by $169777724.38M in total portfolio value
10 years
VBLT
VBLT
● Live price
1282.05%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$169777724.42M
Annual income
$147,192,786,254,209.56
Full VBLT calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — VBLT vs EQR

📍 VBLT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVBLTEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VBLT + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
VBLT pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VBLT
Annual income on $10K today (after 15% tax)
$108,974.36/yr
After 10yr DRIP, annual income (after tax)
$125,113,868,316,078.12/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, VBLT beats the other by $125,113,868,312,831.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VBLT + EQR for your $10,000?

VBLT: 50%EQR: 50%
100% EQR50/50100% VBLT
Portfolio after 10yr
$84888862.23M
Annual income
$73,596,393,129,014.58/yr
Blended yield
86.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

VBLT
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Price Target
$5.00
+3105.1% upside vs current
Range: $5.00 — $5.00
Altman Z
-19.9
Piotroski
0/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VBLT buys
0
EQR buys
0
No recent congressional trades found for VBLT or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVBLTEQR
Forward yield1282.05% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$169777724.42M ✓$40.5K
Annual income after 10y$147,192,786,254,209.56 ✓$3,819.61
Total dividends collected$168105692.30M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$5.00$70.35 ✓

Year-by-year: VBLT vs EQR ($10,000, DRIP)

YearVBLT PortfolioVBLT Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$138,905$128,205.13$11,248$547.57+$127.7K → VBLT
2$1,812,960$1,664,331.75$12,701$666.53+$1.80M → VBLT
3$22,241,274$20,301,406.25$14,405$814.59+$22.23M → VBLT
4$256,561,041$232,762,878.32$16,413$999.84+$256.54M → VBLT
5$2,783,868,903$2,509,348,588.72$18,795$1,232.92+$2783.85M → VBLT
6$28,425,663,485$25,446,923,758.80$21,639$1,527.95+$28425.64M → VBLT
7$273,251,611,466$242,836,151,537.34$25,057$1,903.80+$273251.59M → VBLT
8$2,474,012,179,526$2,181,632,955,256.89$29,197$2,385.87+$2474012.15M → VBLT
9$21,107,418,843,486$18,460,225,811,393.34$34,250$3,008.70+$21107418.81M → VBLT
10$169,777,724,416,739$147,192,786,254,209.56$40,467$3,819.61+$169777724.38M → VBLT

VBLT vs EQR: Complete Analysis 2026

VBLT — Stock

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Full VBLT Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this VBLT vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VBLT vs SCHDVBLT vs JEPIVBLT vs OVBLT vs KOVBLT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.